RLFTY (MindMaze Therapeutics Holding) ROE % Adjusted to Book Value: -5.76% (As of Dec. 2025)


RLFTY MindMaze Therapeutics Holding SA RLFTY
11 GF Score
Price $0.42
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding ROE % Adjusted to Book Value?

MindMaze Therapeutics Holding RLFTY 11 ROE % Adjusted to Book Value is -5.76% as of Dec. 2025. GuruFocus rates RLFTY with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

MindMaze Therapeutics Holding's ROE % for the quarter that ended in Dec. 2025 was -51.57%. MindMaze Therapeutics Holding's PB Ratio for the quarter that ended in Dec. 2025 was 8.95. MindMaze Therapeutics Holding's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -5.76%.

MindMaze Therapeutics Holding ROE % Adjusted to Book Value Related Terms

MindMaze Therapeutics Holding ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding ROE % Adjusted to Book Value Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
ROE % Adjusted to Book Value
0.00 -5.76

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
ROE % Adjusted to Book Value 0.00 -5.76

RLFTY vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's ROE % Adjusted to Book Value falls into.


RLFTY
11GF Score
MindMaze Therapeutics Holding SA RLFTY
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding ROE % Adjusted to Book Value Calculation

MindMaze Therapeutics Holding's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-51.57% / 8.95
=-5.76%

MindMaze Therapeutics Holding's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-51.57% / 8.95
=-5.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -5.76% mean?
MindMaze Therapeutics Holding (RLFTY) has a ROE % Adjusted to Book Value of -5.76% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MindMaze Therapeutics Holding and its competitors.
Is MindMaze Therapeutics Holding's ROE % Adjusted to Book Value too high?
MindMaze Therapeutics Holding's current ROE % Adjusted to Book Value is -5.76%. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's ROE % Adjusted to Book Value compare to VRTX and REGN?
MindMaze Therapeutics Holding's ROE % Adjusted to Book Value of -5.76% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current ROE % Adjusted to Book Value is -5.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current ROE % Adjusted to Book Value of -5.76%. The current ROE % Adjusted to Book Value is -5.76%. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current ROE % Adjusted to Book Value is -5.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindMaze Therapeutics Holding Business Description

Other Exchanges MMTXz:UKMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score

Get the complete analysis for RLFTY

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price